OCS-05 met safety and efficacy endpoints in the treatment of acute optic neuritis in a phase 2 trial, according to a press release from Oculis.
“While the high-dose steroids used today can shorten the acute inflammatory process, there remains an unmet medical need for therapies that preserve neurons from dying and therefore preserve vision,” Riad Sherif, MD, CEO of Oculis, told Healio. “The ACUITY trial’s positive results highlight a neuroprotective structural and anatomical benefit from OCS-05, protecting retinal ganglion cells and the axons, and its ability to improve